233 related articles for article (PubMed ID: 20425392)
1. New drugs for the treatment of myelofibrosis.
Mesa RA
Curr Hematol Malig Rep; 2010 Jan; 5(1):15-21. PubMed ID: 20425392
[TBL] [Abstract][Full Text] [Related]
2. How I treat symptomatic splenomegaly in patients with myelofibrosis.
Mesa RA
Blood; 2009 May; 113(22):5394-400. PubMed ID: 19332765
[TBL] [Abstract][Full Text] [Related]
3. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.
Mesa RA; Tefferi A
Expert Opin Emerg Drugs; 2009 Sep; 14(3):471-9. PubMed ID: 19552608
[TBL] [Abstract][Full Text] [Related]
4. Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia.
Mesa RA; Quintás-Cardama A; Verstovsek S
Curr Hematol Malig Rep; 2007 Feb; 2(1):25-33. PubMed ID: 20425385
[TBL] [Abstract][Full Text] [Related]
5. Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
Randhawa J; Ostojic A; Vrhovac R; Atallah E; Verstovsek S
J Hematol Oncol; 2012 Aug; 5():43. PubMed ID: 22852872
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
Pardanani A; Harrison C; Cortes JE; Cervantes F; Mesa RA; Milligan D; Masszi T; Mishchenko E; Jourdan E; Vannucchi AM; Drummond MW; Jurgutis M; Kuliczkowski K; Gheorghita E; Passamonti F; Neumann F; Patki A; Gao G; Tefferi A
JAMA Oncol; 2015 Aug; 1(5):643-51. PubMed ID: 26181658
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Verstovsek S
Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
[TBL] [Abstract][Full Text] [Related]
8. Myelofibrosis: an update on current pharmacotherapy and future directions.
Cervantes F; Martinez-Trillos A
Expert Opin Pharmacother; 2013 May; 14(7):873-84. PubMed ID: 23514013
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
[TBL] [Abstract][Full Text] [Related]
10. The evolving treatment paradigm in myelofibrosis.
Mesa RA
Leuk Lymphoma; 2013 Feb; 54(2):242-51. PubMed ID: 22793267
[TBL] [Abstract][Full Text] [Related]
11. New approaches to tackle cytopenic myelofibrosis.
Reynolds SB; Pettit K
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):235-244. PubMed ID: 36485113
[TBL] [Abstract][Full Text] [Related]
12. Assessing new therapies and their overall impact in myelofibrosis.
Mesa RA
Hematology Am Soc Hematol Educ Program; 2010; 2010():115-21. PubMed ID: 21239780
[TBL] [Abstract][Full Text] [Related]
13. Myelofibrosis: an update on drug therapy in 2016.
Bose P; Verstovsek S
Expert Opin Pharmacother; 2016 Dec; 17(18):2375-2389. PubMed ID: 27774820
[TBL] [Abstract][Full Text] [Related]
14. How I manage anemia related to myelofibrosis and its treatment regimens.
Verstovsek S
Ann Hematol; 2023 Apr; 102(4):689-698. PubMed ID: 36786879
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia.
Hogan WJ; Litzow MR; Tefferi A
Curr Hematol Malig Rep; 2007 Feb; 2(1):34-42. PubMed ID: 20425386
[TBL] [Abstract][Full Text] [Related]
16. Emerging drugs for myelofibrosis.
Atallah E; Verstovsek S
Expert Opin Emerg Drugs; 2012 Dec; 17(4):555-70. PubMed ID: 23186315
[TBL] [Abstract][Full Text] [Related]
17. Choosing between stem cell therapy and drugs in myelofibrosis.
Kröger N; Mesa RA
Leukemia; 2008 Mar; 22(3):474-86. PubMed ID: 18185525
[TBL] [Abstract][Full Text] [Related]
18. A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.
Ho PJ; Bajel A; Burbury K; Dunlop L; Durrant S; Forsyth C; Perkins AC; Ross DM
Intern Med J; 2017 Mar; 47(3):262-268. PubMed ID: 28260257
[TBL] [Abstract][Full Text] [Related]
19. How I treat myelofibrosis.
Cervantes F
Blood; 2014 Oct; 124(17):2635-42. PubMed ID: 25232060
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Myelofibrosis: A Moving Target.
Cerquozzi S; Farhadfar N; Tefferi A
Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
